Microvascular Endothelial Dysfunction Can Predict Dementia

This article originally appeared here.
Share this content:
Microvascular Endothelial Dysfunction Can Predict Dementia
Microvascular Endothelial Dysfunction Can Predict Dementia

FRIDAY, April 21, 2017 (HealthDay News) -- Markers of microvascular endothelial dysfunction can predict dementia, according to a study published online April 13 in the Journal of Internal Medicine.

Hilma Holm, from Lund University in Malmö, Sweden, and colleagues examined the longitudinal association of midregional pro-atrial natriuretic peptide (MR-proANP), C-terminal endothelin-1 (CT-proET-1), and midregional pro-adrenomedullin (MR-proADM) with dementia in a population-based cohort of 5,347 individuals without prevalent dementia (age, 69 ± 6 years).

Over a period of 4.6 ± 1.3 years, 373 patients were diagnosed with dementia. The researchers found that there were significant associations for higher levels of MR-proANP with increased risk of all-cause and vascular dementia (hazard ratio per one standard deviation, 1.2 and 1.52, respectively). Across quartiles of MR-proANP, there was an increase in the risk of all-cause dementia (hazard ratio, 1.83 for quartile 4 versus 1), which was most pronounced for vascular type (hazard ratio, 2.71). Vascular dementia was predicted by the two highest quartiles of CT-proET-1, with a cut-off value at 68 pmol/L (hazard ratio, 1.94 for quartiles 3 to 4 versus 1 to 2). After adjustment for traditional risk factors, elevated levels of MR-proADM indicated no increased risk of developing dementia.

"Elevated plasma concentration of MR-proANP is an independent predictor of all-cause and vascular dementia," the authors write. "Pronounced increase in CT-proET-1 indicates higher risk of vascular dementia."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths